MannKind (MNKD) 10-Q 10 May 17 2017 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2017	May 05, 2017
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1
Trading Symbol	MNKD
Entity Registrant Name	MANNKIND CORP
Entity Central Index Key	899,460
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		101,006,255

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 47,978	$ 22,895
Accounts receivable, net	438	302
Receivable from Sanofi		30,557
Inventory	3,698	2,331
Asset held for sale		16,730
Deferred costs from commercial product sales	472	309
Prepaid expenses and other current assets	3,508	4,364
Total current assets	56,094	77,488
Property and equipment - net	28,482	28,927
Other assets	609	648
Total assets	85,185	107,063
Current liabilities:
Accounts payable	1,519	3,263
Accrued expenses and other current liabilities	10,657	7,937
Facility financing obligation	71,795	71,339
Deferred revenue - net	1,844	3,419
Deferred payments from collaboration - current	250	1,000
Recognized loss on purchase commitments - current	6,984	5,093
Total current liabilities	93,049	92,051
Note payable to principal stockholder	49,521	49,521
Accrued interest - note payable to principal stockholder	9,995	9,281
Senior convertible notes	27,642	27,635
Recognized loss on purchase commitments - long term	95,062	95,942
Deferred payments from collaboration - long term	687
Warrant liability	752	7,381
Milestone rights liability and other liabilities	7,202	8,845
Total liabilities	283,910	290,656
Commitments and contingencies (Note 10)
Stockholders' deficit:
Undesignated preferred stock, $0.01 par value - 10,000,000 shares authorized; no shares issued or outstanding at March 31, 2017 and December 31, 2016
Common stock, $0.01 par value - 140,000,000 shares authorized, 95,776,297 and 95,680,831 shares issued and outstanding at March 31, 2017 and December 31, 2016, respectively	958	957
Additional paid-in capital	2,554,230	2,553,039
Accumulated other comprehensive loss	(24)	(24)
Accumulated deficit	(2,753,889)	(2,737,565)
Total stockholders' deficit	(198,725)	(183,593)
Total liabilities and stockholders' deficit	$ 85,185	$ 107,063

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2017	Dec. 31, 2016
Undesignated preferred stock, par value	$ 0.01	$ 0.01
Undesignated preferred stock, shares authorized	10,000,000	10,000,000
Undesignated preferred stock, shares issued	0	0
Undesignated preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	140,000,000	140,000,000
Common stock, shares issued	95,776,297	95,680,831
Common stock, shares outstanding	95,776,297	95,680,831

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenues:
Net revenue - collaboration	$ 63
Net revenue - commercial product sales	1,196
Revenue - bulk insulin sales	1,750
Total revenues	3,009
Expenses:
Cost of goods sold	2,548	$ 5,168
Research and development	3,129	5,130
Selling, general and administrative	15,389	7,351
Loss on foreign currency translation	1,545	2,364
Total expenses	22,611	20,013
Loss from operations	(19,602)	(20,013)
Other income (expense):
Change in fair value of warrant liability	6,629
Interest income	55	15
Interest expense on notes	(2,706)	(4,221)
Interest expense on note payable to principal stockholder	(714)	(721)
Other income	14	67
Total other income (expense)	3,278	(4,860)
Loss before benefit for income taxes	(16,324)	(24,873)
Income tax benefit	0	0
Net loss	$ (16,324)	$ (24,873)
Net loss per share - basic and diluted	$ (0.17)	$ (0.29)
Shares used to compute basic and diluted net loss per share	95,744	85,772

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Net loss	$ (16,324)	$ (24,873)
Other comprehensive loss:
Cumulative translation gain		1
Comprehensive loss	$ (16,324)	$ (24,872)

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (16,324)	$ (24,873)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation, amortization and accretion	908	1,023
Stock-based compensation expense	1,267	1,273
Loss on foreign currency translation	1,545	2,364
Interest incurred through borrowings under Sanofi Loan Facility		1,168
Interest on note payable to principal stockholder	714	721
Change in fair value of warrant liability	(6,629)
Other, net		696
Changes in operating assets and liabilities:
Accounts receivable, net	(136)	(121)
Receivable from Sanofi	30,557
Inventory	(1,367)
Deferred costs from commercial product sales	(163)
Prepaid expenses and other current assets	856	1,211
Other assets	39	(86)
Accounts payable	(1,665)	(14,799)
Accrued expenses and other current liabilities	1,077	488
Deferred payments from collaboration	(63)	177
Deferred revenue - net	(1,575)
Recognized loss on purchase commitments	(534)
Net cash provided by (used in) operating activities	8,507	(30,758)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment		(1,144)
Net proceeds from sale of property and equipment	16,651	17
Net cash provided by (used in) investing activities	16,651	(1,127)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock		467
Payment of employment taxes related to vested restricted stock units	(75)	(3)
Net cash provided by (used in) financing activities	(75)	464
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	25,083	(31,421)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	22,895	59,074
CASH AND CASH EQUIVALENTS, END OF PERIOD	47,978	27,653
SUPPLEMENTAL CASH FLOWS DISCLOSURES:
Interest paid in cash, net of amounts capitalized	$ 2,550	2,713
Cost incurred for construction in progress included in accounts payable and accrued liabilities		$ 558

Description of Business and Sig

Description of Business and Significant Accounting Policies	3 Months Ended
	Mar. 31, 2017
Description of Business and Significant Accounting Policies	1. Description of Business and Significant Accounting Policies The accompanying unaudited condensed consolidated financial statements of MannKind Corporation and its subsidiaries (“MannKind,” the “Company,” “we” or “us”), have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (the “SEC”). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The information included in this quarterly report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2016 filed with the SEC on March 16, 2017 (the “Annual Report”). In the opinion of management, all adjustments, consisting only of normal, recurring adjustments, considered necessary for a fair presentation of the results of these interim periods have been included. The results of operations for the three months ended March 31, 2017 may not be indicative of the results that may be expected for the full year. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates or assumptions. Management considers many factors in selecting appropriate financial accounting policies, and in developing the estimates and assumptions that are used in the preparation of the financial statements. Management must apply significant judgment in this process. The more significant estimates reflected in these accompanying condensed consolidated financial statements include revenue recognition, assessing long-lived assets and deferred product costs for impairment, accrued expenses, inventory recoverability, valuation of the facility financing obligation, loss on purchase commitments, warrant liability, milestone rights, stock-based compensation and the determination of the provision for income taxes and corresponding deferred tax assets and liabilities and any valuation allowance recorded against net deferred tax assets. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Business On August 11, 2014, the Company executed a license and collaboration agreement (the “Sanofi License Agreement”) with Sanofi-Aventis Deutschland GmbH, which subsequently assigned its rights and obligations under the agreement to Sanofi-Aventis U.S. LLC (“Sanofi”), pursuant to which Sanofi was responsible for global commercial, regulatory and development activities for Afrezza. On January 4, 2016, the Company received written notification from Sanofi of its election to terminate in its entirety the Sanofi License Agreement. The effective date of termination was April 4, 2016, which was when the Company assumed responsibility for worldwide development and commercialization of Afrezza. Under the terms of the transition agreement, Sanofi continued to fulfill orders for Afrezza in the United States until the Company began distributing MannKind-branded Afrezza product to major wholesalers in late July 2016. The Company began recognizing commercial product sales revenue when MannKind-branded Afrezza was dispensed from pharmacies to patients in August 2016. On November 9, 2016, the Company entered into a settlement agreement with Sanofi (the “Settlement Agreement”). Under the terms of the Settlement Agreement, the promissory note (the “Sanofi Loan Facility”) between the Company and Aventisub LLC (“Aventisub”), a Sanofi affiliate, was terminated with Aventisub agreeing to fully forgive the outstanding loan balance of $72.0 million. Sanofi also purchased $10.2 million of insulin from the Company in December 2016 under an existing insulin put option and made a cash payment of $30.6 million to the Company in early January 2017 as acceleration and in replacement of all other payments that Sanofi would otherwise have been required to make in the future pursuant to the insulin put option, without the Company being required to deliver any insulin for such payment. The Company was also relieved of its obligation to pay Sanofi $0.5 million in previously uncharged costs pursuant to the Sanofi License Agreement. The Company and Sanofi also agreed to a general release of potential claims against each other. During their initial transition of the commercial responsibilities from Sanofi, the Company utilized a contract sales organization to promote Afrezza while the Company focused its internal resources on establishing a channel strategy, entering into distribution agreements and developing co-pay assistance programs, a voucher program, data agreements and payor relationships. In early 2017, the Company recruited its own sales force and intends to continue the commercialization of Afrezza in the United States through its own commercial organization. The Company’s current strategy for future commercialization of Afrezza outside of the United States, subject to receipt of the necessary foreign regulatory approvals, is to seek and establish partnerships in foreign jurisdictions where there are appropriate commercial opportunities. As of and for the three months ended March 31, 2017, the Company has reported an accumulated deficit of $2.8 billion and has reported negative cash flow from operations for each year since inception, except for the current quarter, when the Company received the $30.6 million settlement payment from Sanofi and in 2014, when the Company received the $150.0 million upfront payment from Sanofi. At March 31, 2017, the Company’s capital resources consisted of cash and cash equivalents of $48.0 million. The Company expects to continue to incur significant expenditures to support commercial manufacturing and sales and marketing of Afrezza and the development of their product candidates. The facility agreement (the “Facility Agreement”) with Deerfield Private Design Fund II, L.P. (“Deerfield Private Design Fund”) and Deerfield Private Design International II, L.P. (collectively, “Deerfield”) that resulted in the issuance of 9.75% Senior Convertible Notes due 2019 (“2019 notes”) and the First Amendment to Facility Agreement and Registration Rights Agreement (the “First Amendment”) that resulted in the issuance of an additional tranche of 8.75% Senior Convertible Notes due 2019 (“Tranche B notes”) (see Note 6 — Borrowings) requires the Company to maintain at least $25.0 million in cash and cash equivalents or available borrowings under the loan arrangement, dated as of October 2, 2007, between the Company and The Mann Group LLC (as amended, restated, or otherwise modified as of the date hereof, “The Mann Group Loan Arrangement”), as of the last day of each fiscal quarter. Additional funding sources that are, or in certain circumstances may be, available to the Company include $30.1 million principal amount of available borrowings under The Mann Group Loan Arrangement. A portion of these available borrowings may be used to capitalize accrued interest into principal, upon mutual agreement of the parties, as it becomes due and payable under The Mann Group Loan Arrangement (see Note 5 — Related-Party Arrangements). The Company is seeking and will need to raise additional capital, whether through a sale of equity or debt securities, a strategic business collaboration with another company, the establishment of other funding facilities, licensing arrangements, asset sales or other means, in order to continue the development and commercialization of Afrezza and other product candidates and to support its other ongoing activities. The Company cannot provide assurances that such additional capital will be available on acceptable terms or at all. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. On September 14, 2016, the Company received notice from the Listing Qualifications Department of the NASDAQ Stock Market indicating that in the previous 30 consecutive business days, the bid price for the common stock closed below the minimum of $1.00 per share required for continued inclusion on the NASDAQ Global Market. The notification letter stated that the Company would be afforded 180 calendar days, or until March 13, 2017, to regain compliance with the minimum bid price requirement. On March 16, 2017, the Company received a letter from the Listing Qualifications Department of the NASDAQ Global Market indicating that the Company had regained compliance with the $1.00 minimum closing bid requirement following completion of the reverse stock split described below. On March 1, 2017, following stockholder approval, the Company’s board of directors approved a reverse stock split ratio of 1-for-5. On March 1, 2017, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment of the Company’s Amended and Restated Certificate of Incorporation to effect the 1-for-5 reverse stock split of the Company’s outstanding common stock and to reduce the authorized number of shares of the Company’s common stock from 700,000,000 to 140,000,000 shares. The Company’s common stock began trading on the NASDAQ Global Market on a split-adjusted basis when the market opened on March 3, 2017. As a result, all common stock share amounts included in these condensed consolidated financial statements have been retroactively reduced by a factor of five, and all common stock per share amounts have been increased by a factor of five, with the exception of the Company’s common stock par value. On April 18, 2017, the Company entered into an Exchange Agreement with Deerfield resulting in the cash repayment of $4.0 million under the Tranche B notes and the conversion of $1.0 million and $5.0 million of the Tranche B notes and the 2019 notes, respectively to common shares (see Note 13, Subsequent Events for disclosure of the Exchange Agreement). Reclassifications Correction of an Immaterial Error 2016 as Previously 2016 as (In thousands) Presented Adjustments Adjusted Common stock $ 4,784 $ (3,827 ) $ 957 Additional paid-in capital $ 2,549,212 $ 3,827 $ 2,553,039 Revenue Recognition Revenue Recognition – Net Revenue – Collaborations – Revenue Recognition – Net Revenue – Commercial Product Sales – Given the Company’s limited sales history for Afrezza, the Company cannot reliably estimate expected returns of the product at the time of shipment into the distribution channel. Accordingly, the Company defers recognition of revenue on Afrezza product shipments until the right of return no longer exists, which occurs at the earlier of the time Afrezza is dispensed from pharmacies to patients or expiration of the right of return. Deferred revenue is presented net of deferred product sales discounts which are further described in Gross-to-Net Adjustments For the three months ended March 31, 2017, net revenue from commercial product sales consisted of $1.2 million of net sales of Afrezza dispensed to patients. As of March 31, 2017 and December 31, 2016, the ending balances for deferred revenue were $1.8 million and $3.4 million, on its condensed consolidated balance sheets, of which $1.8 million and $1.6 million (net of estimated gross-to-net adjustments), respectively, represents product shipped to the Company’s third-party logistics provider and wholesale distributors, but not yet dispensed to patients. The difference, as of December 31, 2016, represented deferred revenue from bulk insulin sales, which is described more fully under the heading Revenue Recognition – Revenue – Bulk Insulin Sales Gross-to-net Adjustments – Wholesaler Distribution Fees – Prompt Pay Discounts – Rebates and Chargebacks – The Company accounts for these rebates and chargebacks by establishing an accrual based on contractual discount rates, expected utilization under each contract and an estimate of the amount of inventory in the distribution channel that will become subject to such rebates and chargebacks based on historical payor data provided by a third-party vendor along with additional data including a forecasted participation rates. From that data, as well as input received from the commercial team, an estimated participation rate for each program is determined and applied at the rate for those sales. Any new information regarding changes in the programs’ regulations and guidelines or any changes in the Company’s government price reporting calculations that would impact the amount of the rebates will also be taken into account in determining or modifying the appropriate reserve. The time period between the date the product is sold into the channel and the date such rebates may be paid can be up to approximately six to nine months. As such, continuous monitoring of these estimates will be performed on a periodic basis, and if necessary, adjusted to reflect new facts and circumstances. Rebates and chargebacks are recognized as a reduction of gross revenue in the period the related revenue is recognized. Other Rebates and Discounts – Patient Discount and Co-Pay Assistance Programs – Deferred Costs from Commercial Product Sales Revenue Recognition — Revenue — Bulk Insulin Sales Cost of Goods Sold Accounts Receivable and Allowances Inventories Recognized Loss on Purchase Commitments Fair Value of Financial Instruments Stock-Based Compensation Warrants Net Loss Per Share of Common Stock The computation of basic and diluted net loss per share for the three months ended March 31, 2017 and 2016 excludes the common stock equivalents of the following potentially dilutive securities because their inclusion would be anti-dilutive: Three Months Ended March 31, 2017 2016 Restricted stock units 709,004 789,201 Senior convertible notes 814,561 814,561 Warrants 9,740,597 31,861 Stock options 5,941,408 4,820,494 17,205,570 6,456,117 Recently Issued Accounting Standards – In May 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606), Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date The Company will adopt the new guidance for the year beginning January 1, 2018. The Company has the option to either apply the new guidance retrospectively for all prior reporting periods presented (full retrospective) or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (modified retrospective). The Company currently anticipates it will apply the new guidance using the modified retrospective approach with the cumulative effect of initial application recognized as of January 1, 2018. The Company plans to continue analyzing the potential impacts of the application throughout 2017 and, depending on factors that may impact the results, could elect to apply the new guidance on a full retrospective basis. Currently, for commercial sales of Afrezza, the Company has limited sales and returns history, and as such is unable to reliably estimate expected returns of the product at the time of shipment into the distribution channel. Accordingly, the Company defers recognition of revenue on Afrezza product shipments until the right of return no longer exists, which occurs at the earliest of the time Afrezza is dispensed form pharmacies to patients or expiration of the right of return. The Company recognizes revenue based on Afrezza patient prescriptions dispensed, a sell-through model, as estimated by syndicated data provided by a third party. The Company also analyzes additional data points to ensure that such third-party data is reasonable, including data related to inventory movements within the channel and ongoing prescription demand. Upon adoption of the new guidance, the Company expects that it will move from its current sell-through model to a sell-to model for revenue related to commercial sales of Afrezza and will record revenue at the time title and risk of loss passes to its distributors (generally at shipment or delivery to the distributors) along with an estimate of potential returns as variable consideration. The Company also anticipates that its ability to estimate potential returns will improve with an additional 9 months of sales history that it will have obtained by January 1, 2018. Additionally, the Company has historically entered into collaborative agreements with third-parties under which periodic payments have been received. Revenue recognition for certain payments received have been deferred until the price is fixed and determinable. Further, revenue for certain payments to be received in the future has been prohibited from recognition until received. The Company expects that some of these amounts will be considered variable consideration and may be able to be recognized earlier under the new guidance. The Company has begun its evaluation of the impact of adoption and plans to continue its evaluation throughout 2017. The financial impact upon the adoption will be dependent upon a number of factors including; the amount of revenue that has been deferred under the sell-through model for Afrezza, the amount of the revenue deferred under collaborative arrangements and the Company’s estimate of variable consideration at the date of adoption. At this time, the Company has not completed its evaluation of the inputs, assumptions and methodologies that will be used recognize revenue related to variable consideration under the new guidance. In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments Overall (Subtopic 825-10) Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 84 In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2017
Inventories	2. Inventories Inventories consist of the following (in thousands): March 31, 2017 December 31, 2016 Work-in-process $ 3,296 $ 2,120 Finished goods 402 211 Total inventory $ 3,698 $ 2,331 Work-in-process and finished goods as of March 31, 2017 and December 31, 2016 include conversion costs but not materials cost because the materials used in its production were previously written off.

Property and Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2017
Property and Equipment	3. Property and Equipment Property and equipment consist of the following (in thousands): Estimated Useful Life (Years) March 31, 2017 December 31, 2016 Land — $ 875 $ 875 Buildings 39-40 17,389 17,389 Building improvements 5-40 34,957 34,957 Machinery and equipment 3-15 62,992 62,992 Furniture, fixtures and office equipment 5-10 3,556 3,556 Computer equipment and software 3 8,531 8,531 Construction in progress — 202 202 128,502 128,502 Less accumulated depreciation (100,020 ) (99,575 ) Total property and equipment, net $ 28,482 $ 28,927 Depreciation and amortization expense related to property and equipment for the three months ended March 31, 2017 and 2016 was $0.4 million and $0.6 million, respectively. On January 6, 2017, the Company and Rexford Industrial Realty, L.P. (“Rexford”) entered into an Agreement of Purchase and Sale and Joint Escrow Instructions (the “Purchase Agreement”), pursuant to which the Company agreed to sell and Rexford agreed to purchase certain parcels of real estate owned by the Company in Valencia, California and certain related improvements, personal property, equipment, supplies and fixtures (collectively, the “Property”) for $17.3 million. The sale and purchase of the aforementioned Property for $17.3 million pursuant to the terms of the Purchase Agreement, as amended, was completed on February 17, 2017. Net proceeds were $16.7 million after deducting broker’s commission and other fees of approximately $0.6 million paid by the Company. Net proceeds received approximated the carrying value of the asset held for sale.

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	3 Months Ended
	Mar. 31, 2017
Accrued Expenses and Other Current Liabilities	4. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consist of the following (in thousands): March 31, 2017 December 31, 2016 Salary and related expenses $ 3,900 $ 3,814 Current portion of milestone rights liability 1,643 — Professional fees 1,505 875 Discounts and allowances for commercial product sales 996 754 Sales and marketing services 821 144 Restructuring 772 1,376 Accrued interest 221 619 Other 799 355 Accrued expenses and other current liabilities $ 10,657 $ 7,937

Related-Party Arrangements

Related-Party Arrangements	3 Months Ended
	Mar. 31, 2017
Related-Party Arrangements	5. Related-Party Arrangements In October 2007, the Company entered into The Mann Group Loan Arrangement, which has been amended from time to time. On October 31, 2013, the promissory note underlying The Mann Group Loan Arrangement was amended to, among other things, extend the maturity date of the loan to January 5, 2020, extend the date through which the Company can borrow under The Mann Group Loan Arrangement to December 31, 2019, increase the aggregate borrowing amount under The Mann Group Loan Arrangement from $350.0 million to $370.0 million and provide that repayments or cancellations of principal under The Mann Group Loan Arrangement will not be available for reborrowing. As of March 31, 2017, the total principal amount outstanding under The Mann Group Loan Arrangement was $49.5 million, and the amount available for future borrowings was $30.1 million. Interest, at a fixed rate of 5.84%, is due and payable quarterly in arrears on the first day of each calendar quarter for the preceding quarter, or at such other time as the Company and The Mann Group mutually agree. All or any portion of accrued and unpaid interest that becomes due and payable may be paid-in-kind and capitalized as additional borrowings at any time and would be classified as non-current. The Mann Group can require the Company to prepay up to $200.0 million in advances that have been outstanding for at least 12 months, less approximately $105.0 million aggregate principal amount that has been cancelled in connection with two common stock purchase agreements. If The Mann Group exercises this right, the Company will have 90 days after The Mann Group provides written notice, or the number of days to maturity of the note if less than 90 days, to prepay such advances. However, pursuant to a letter agreement entered into in August 2010, The Mann Group has agreed to not require the Company to prepay amounts outstanding under the amended and restated promissory note if the prepayment would require the Company to use its working capital resources. In addition, The Mann Group entered into a subordination agreement with Deerfield pursuant to which The Mann Group agreed with Deerfield not to demand or accept any payment under The Mann Group Loan Arrangement until the Company’s payment obligations to Deerfield under the Facility Agreement have been satisfied in full. Subject to the foregoing, in the event of a default under The Mann Group Loan Arrangement, all unpaid principal and interest either becomes immediately due and payable or may be accelerated at The Mann Group’s option, and the interest rate will increase to the one-year LIBOR calculated on the date of the initial advance or in effect on the date of default, whichever is greater, plus 5% per annum. All borrowings under The Mann Group Loan Arrangement are unsecured. The Mann Group Loan Arrangement contains no financial covenants. As of March 31, 2017 and December 31, 2016, the Company had accrued and unpaid interest related to the above note of $10.0 million and $9.3 million, respectively, and had $30.1 million of available borrowings. Interest expense on the Company’s note payable to the Company’s principal stockholder for the three months ended March 31, 2017 and 2016 were $0.7 million and $0.7 million, respectively. In May 2015, the Company entered into a sublease agreement with the Alfred Mann Foundation for Scientific Research (the “Mann Foundation”), a California not-for-profit corporation. The lease is for approximately 12,500 square feet of office space in Valencia, California which expired in April 2017 and was renewed on a month-to-month basis at a rate of $21,000 per month. The office space contains the Company’s principal executive offices. Lease payments to the Mann Foundation for the three months ended March 31, 2017 and 2016 were $62,000 and $65,000, respectively. The Company has entered into indemnification agreements with each of its directors and executive officers, in addition to the indemnification provided for in its amended and restated certificate of incorporation and amended and restated bylaws (see Note 10 — Commitments and Contingencies).

Borrowings

Borrowings	3 Months Ended
	Mar. 31, 2017
Borrowings	6. Borrowings Borrowings consist of the following (in thousands): March 31, 2017 December 31, 2016 Facility Financing Obligation (2019 Notes) Principal amount $ 75,000 $ 75,000 Unamortized debt discount (3,205 ) (3,661 ) Net carrying amount $ 71,795 $ 71,339 Senior Convertible Notes (2018 Notes) Principal amount $ 27,690 $ 27,690 Unamortized premium 367 426 Unaccreted debt issuance costs (415 ) (481 ) Net carrying amount $ 27,642 $ 27,635 Note payable to principal stockholder - net carrying amount $ 49,521 $ 49,521 Facility Financing Obligation (2019 Notes) In conjunction with the Facility Agreement, the Company entered into a Milestone Rights Agreement with Deerfield which requires the Company to make contingent payments to Deerfield, totaling up to $90.0 million, upon the Company achieving specified commercialization milestones. As of March 31, 2017 and December 31, 2016, the remaining milestone rights liability balance was $8.9 million. The Company currently estimates that it will make the next milestone payment in the first quarter of 2018. Accordingly, $1.6 million in value related to the next milestone payment was recorded in accrued expenses and other current liabilities as of March 31, 2017, resulting in $7.3 million and $8.9 million being recorded in milestone rights liability and other liabilities, which is non-current, in the accompanying condensed consolidated balance sheets as of March 31, 2017 and December 31, 2016, respectively. Accretion of debt issuance cost and debt discount in connection with the Facility Agreement during the three months ended March 31, 2017 and 2016 are as follows (in thousands): Three Months Ended March 31, 2017 2016 Accretion expense - debt issuance cost $ 9 $ 9 Accretion expense - debt discount $ 447 $ 419 The Facility Agreement includes customary representations, warranties and covenants, including a restriction on the incurrence of additional indebtedness, and a financial covenant which requires the Company’s cash and cash equivalents, which include available borrowings on the note payable to a principal stockholder, on the last day of each fiscal quarter to not be less than $25.0 million. As discussed in Note 1 – Description of Business and Summary of Significant Accounting Policies, the Company will need to raise additional capital to support its current operating plans. Due to the uncertainties related to maintaining sufficient resources to comply with the aforementioned covenant, the 2019 notes and Tranche B notes have been classified as current liabilities in the accompanying condensed consolidated balance sheets as of March 31, 2017 and December 31, 2016. In the event of non-compliance, Deerfield may declare all or any portion of the 2019 notes and/or Tranche B notes to be immediately due and payable. Milestone Rights Security Agreement Embedded Derivatives de minimis Conversion Option — Issuance of new 5.75% Convertible Senior Subordinated Exchange Notes Due 2018 in Exchange for 2015 Notes The 2018 notes are convertible, at the option of the holder, at any time on or prior to the close of business on the business day immediately preceding the stated maturity date, into shares of the Company’s common stock at an initial conversion rate of 29 shares per $1,000 principal amount of 2018 notes, which is equal to a conversion price of approximately $34.00 per share, the same conversion price as that of the 2015 notes on the date of exchange. The conversion rate is subject to adjustment under certain circumstances described in an indenture governing the 2018 notes dated August 10, 2015 with US Bank (as successor trustee to Wells Fargo, National Association), including in connection with a make-whole fundamental change. If certain fundamental changes occur, the Company will be obligated to pay a make-whole premium on any 2018 notes converted in connection with such fundamental change by increasing the conversion rate on such 2018 notes. If the Company undergoes certain fundamental changes, except in certain circumstances, each holder of 2018 notes will have the option to require the Company to repurchase all or any portion of that holder’s 2018 notes. The fundamental change repurchase price will be 100% of the principal amount of the 2018 notes to be repurchased plus accrued and unpaid interest, if any. On or after the date that is one year following the original issue date of the 2018 notes, the Company will have the right to redeem for cash all or part of the 2018 notes if the last reported sale price of its common stock exceeds 130% of the conversion price then in effect for 20 or more trading days during the 30 consecutive trading day period ending on the trading day immediately prior to the date of the redemption notice. The redemption price will equal the sum of 100% of the principal amount of the 2018 notes to be redeemed, plus accrued and unpaid interest. Under the terms of the indenture, the conversion option can be net-share settled and the maximum number of shares that could be required to be delivered under the indenture, including the make-whole shares, is fixed and less than the number of authorized and unissued shares less the maximum number of shares that could be required to be delivered during the term of the 2018 notes under existing commitments. Applying the Company’s sequencing policy, the Company performed an analysis at the time of the offering of the 2018 notes and each reporting date since and has concluded that the number of available authorized shares at the time of the offering and each subsequent reporting date was sufficient to deliver the number of shares that could be required to be delivered during the term of the 2018 notes under existing commitments. The 2018 notes provide that upon an acceleration of certain indebtedness, including the 2019 notes and the Tranche B notes issued to Deerfield pursuant to the Facility Agreement, the holders may elect to accelerate the Company’s repayment obligations under the notes if such acceleration is not cured, waived, rescinded or annulled. There can be no assurance that the holders would not choose to exercise these rights in the event such events were to occur. The Company incurred approximately $0.8 million in issuance costs, which are recorded as an offset to the 2018 notes, in the accompanying condensed consolidated balance sheets. These costs are being accreted to interest expense using the effective interest method over the term of the 2018 notes. Amortization of the premium related to the 2018 notes was $59,000 and $57,000 during the three months ended March 31, 2017 and 2016, respectively. Accretion of debt issuance costs related to the 2018 notes was $66,000 and $62,000 during the three months ended March 31, 2017 and 2016, respectively.

Collaboration Arrangements

Collaboration Arrangements	3 Months Ended
	Mar. 31, 2017
Collaboration Arrangements	7. Collaboration Arrangements Receptor Collaboration and License Agreement The Company received $0.4 million in nonrefundable payments in 2016 prior to Receptor exercising the option. On December 30, 2016, following successful completion of the studies, Receptor exercised its option and paid the Company a $1.0 million nonrefundable option exercise and license fee. Under the CLA, the Company may receive the following additional payments: • Nonrefundable milestone payments upon the completion of certain technology transfer activities and the achievement of specified sales targets; • Royalties upon Receptor’s and its sublicensees’ sale of the product; and • Milestones upon total worldwide sales reaching certain agreed upon levels. The Company evaluated the accounting for the payments received in 2016 under the multiple element accounting guidance and determined that the $0.4 million in payments received prior to Receptor exercising its option are separable from the other elements of the agreement and represented payments to offset costs incurred. Therefore, those payments reduced the Company’s research and development expense in 2016. The $1.0 million license fee received in 2016 does not have standalone value from the follow-on transfer of technology. Therefore, the license fee was recorded in deferred payments from collaboration as of December 31, 2016 and will be recognized in net revenue — collaboration over four years. Recognized revenue related to this license agreement amounted to $0.1 million for the three months ended March 31, 2017. See Note 1 — Description of Business and Summary of Significant Accounting Policies for additional information on the Company’s accounting for multiple element arrangements. On March 15, 2017, the Company entered into a Manufacturing and Supply Agreement with Receptor pursuant to which the Company will provide certain raw materials to Receptor. On March 16, 2017, the Company agreed to provide certain additional research and formulation consulting services to Receptor. Sanofi License Agreement and Sanofi Supply Agreement During the term of the Sanofi License Agreement, worldwide profits and losses were determined based on the difference between the net sales of Afrezza and the costs and expenses incurred by the Company and Sanofi that were specifically attributable or related to the development, regulatory filings, manufacturing, or commercialization of Afrezza. These profits and losses were shared 65% by Sanofi and 35% by the Company. On January 4, 2016, the Company received a 90-day notification from Sanofi of its election to terminate in its entirety the Sanofi License Agreement. The effective date of termination was April 4, 2016. On April 5, 2016, the Company assumed responsibility for the worldwide development and commercialization of Afrezza from Sanofi. Under the terms of the transition agreement, Sanofi continued to fulfill orders for Afrezza in the United States until the Company began distributing MannKind-branded Afrezza product to major wholesalers during the week of July 25, 2016. The Company analyzed the agreements entered into with Sanofi at their inception and determined that prior to December 31, 2015, because the Company did not have the ability to estimate the amount of costs that would potentially be incurred under the loss share provision related to the Sanofi License Agreement and the Sanofi Supply Agreement, the Company recorded the $150.0 million up-front payment and the two milestone payments of $25.0 million each as deferred payments from collaboration. In addition, as of December 31, 2015, the Company had recorded $17.5 million in Afrezza product shipments to Sanofi as deferred sales from collaboration and recorded $13.5 million as deferred costs from collaboration. Deferred costs from collaboration represented the costs of product manufactured and shipped to Sanofi, as well as certain direct costs associated with a firm purchase commitment entered into in connection with the collaboration with Sanofi. During the three months ended September 30, 2016, Sanofi provided enough information to the Company to enable it to reasonably estimate the remaining costs under the Sanofi License Agreement and the Sanofi Supply Agreement. Accordingly, the fixed or determinable fee requirement for revenue recognition was met and there were no future obligations to Sanofi. Therefore, the Company recognized $172.0 million of net revenue — collaboration for the year ended December 31, 2016. The revenue recognized includes the upfront payment of $150.0 million and the two milestone payments of $25.0 million each, net of $64.9 million of net loss share with Sanofi, as well as $17.5 million in sales of Afrezza and $19.4 million from sales of bulk insulin, both to Sanofi. These payments and sales were made pursuant to the contractual terms of the agreements with Sanofi. Sanofi Loan Facility Advances under the Sanofi Loan Facility bore interest at a rate of 8.5% per annum and were payable in-kind and compounded quarterly and added to the outstanding principal balance under the Sanofi Loan Facility. The Company was required to make mandatory prepayments on the outstanding loans under the Sanofi Loan Facility from its share of any profits (as defined in the Sanofi License Agreement) under the Sanofi License Agreement within 30 days of receipt of its share of any such profits. The Company’s total portion of the loss sharing was $57.7 million for the year ended December 31, 2015, of which $44.5 million was borrowed under the Sanofi Loan Facility as of December 31, 2015. Subsequent to December 31, 2015, the Company borrowed $17.9 million under the Sanofi Loan Facility to finance the portion of the Company’s loss for the quarters ended December 31, 2015 and March 31, 2016. The total amount owed to Sanofi at September 30, 2016 was $71.2 million, which included $5.8 million of paid-in-kind interest. On November 9, 2016, the Company entered into a settlement agreement with Sanofi (the “Settlement Agreement”). Under the terms of the Settlement Agreement, the promissory note between the Company and Aventisub LLC, a Sanofi affiliate, was terminated, with Aventisub agreeing to forgive the full outstanding loan balance of $72.0 million. Sanofi also agreed to purchase $10.2 million of insulin from the Company in December 2016 under an existing insulin put option as well as make a cash payment of $30.6 million to the Company in early January 2017 as acceleration and in replacement of all other payments that Sanofi would otherwise have been required to make in the future pursuant to the insulin put option, without the Company being required to deliver any insulin for such payment. The Company was also relieved of its obligation to pay Sanofi $0.5 million in previously uncharged costs pursuant to the Sanofi License Agreement. The Company and Sanofi also agreed to a general release of potential claims against each other. The settlement was accounted for in the year ended December 31, 2016, except for the $30.6 million cash payment received under the insulin put option agreement which reduced the receivable from Sanofi between December 31, 2016 and March 31, 2017.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2017
Fair Value of Financial Instruments	8. Fair Value of Financial Instruments The Company applies various valuation approaches in determining the fair value of its financial assets and liabilities within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is broken down into three levels based on the source of inputs as follows: Level 1— Quoted prices for identical instruments in active markets. Level 2— Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable. Level 3— Significant inputs to the valuation model are unobservable. The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level input that is significant to the overall fair value measurement. Cash Equivalents Note Payable to Principal Stockholder Financial Liabilities As of March 31, 2017 Carrying Value Level 1 Level 2 Level 3 Total Financial liabilities: Senior convertible notes $ 27.6 $ — $ — $ 23.1 $ 23.1 Facility financing obligation 71.8 — — 74.8 74.8 Milestone rights 8.9 — — 18.9 18.9 Warrant liability (at recurring fair value) 0.8 — — 0.8 0.8 Total financial liabilities $ 109.1 $ — $ — $ 117.6 $ 117.6 As of December 31, 2016 Carrying Value Level 2 Level 2 Level 3 Total Financial liabilities: Senior convertible notes $ 27.6 $ — $ — $ 22.9 $ 22.9 Facility financing obligation 71.3 — — 74.5 74.5 Milestone rights 8.9 — — 18.4 18.4 Warrant liability (at recurring fair value) 7.4 — — 7.4 7.4 Total financial liabilities $ 115.2 $ — $ — $ 123.2 $ 123.2 As of March 31, 2017 and December 31, 2016, the fair value of the warrant liability was $0.8 million and $7.4 million, respectively. The fair value of the warrants liability as of March 31, 2017 was estimated using a Monte Carlo valuation pricing model with the following underlying assumptions: (a) a risk-free interest rate of 1.24%; (b) an assumed dividend yield of zero percent; (c) an expected term of 1.1 years; and (d) an expected volatility of 100%. The following table provides a roll forward of the fair value of the warrant liability which is the only Level 3 financial instrument that is carried at fair value (in millions): Warrants Fair value, January 1, 2017 $ 7.4 Additions — Changes in fair value (6.6 ) Payments — Fair value, March 31, 2017 $ 0.8 Senior Convertible Notes Facility Agreement Milestone Rights Liability Warrant Liability — Embedded Derivatives de minimis

Stock-Based Compensation Expens

Stock-Based Compensation Expense	3 Months Ended
	Mar. 31, 2017
Stock-Based Compensation Expense	9. Stock-Based Compensation Expense In March 2016, the FASB issued ASU No. 2016-09, Compensation—Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting • The Company, as of December 31, 2016, had not recognized $11.6 million of excess tax benefits related to windfalls. As a result of adoption, it will now recognize these benefits as deferred tax assets. However, after assessment for realizability, the Company has also recorded a full valuation allowance against the deferred tax assets. This resulted in a zero cumulative effect adjustment to accumulated deficit as a result of the adoption. For the quarter ended March 31, 2017, all shortfalls related to non-qualified options and restricted stock units have been recorded as an income tax expense for the period, offset by a full valuation allowance. • Due to the full valuation allowance for the Company’s deferred tax assets, the excess income tax benefits have never been recorded in additional paid-in-capital. The Company does not contemplate any impact going forward as any amounts to be recorded in the condensed consolidated statements of operations would be fully offset by the valuation allowance nor result in a related classification in cash flows for operating activities. • The Company will continue to recognize forfeitures through estimates consistent with our past practices as opposed to when they occur. • The Company already classifies cash paid to taxing authorities arising from the withholding of shares from employees in cash flows from financing activities. Total stock-based compensation expense recognized in the accompanying condensed consolidated statements of operations for the three months ended March 31, 2017 and 2016 was $1.3 million for both periods. During the three months ended March 31, 2017, the Company issued 77,680 restricted units to certain employees which vest over a four-year period. The grant date fair value of the restricted stock units was $0.2 million with a weighted average grant date fair value per share of $2.70. During the three months ended March 31, 2017, the Company granted certain employees stock options to purchase an aggregate of 583,180 shares of common stock at a weighted average exercise price of $2.70 per share of which 463,000 of these awards vest in four equal tranches upon the achievement of certain product sales targets. The remaining 120,180 options vest over a four year period. The grant date fair value of these awards is $1.1 million with a weighted average grant date fair value of $1.86 per share, as determined using a Black-Scholes option pricing model. As of March 31, 2017, there was $4.1 million, $3.3 million and $3.8 million of unrecognized compensation expense related to restricted stock units, options with performance conditions and options that vest over the vesting period, respectively, which are expected to be recognized over the weighted average vesting period of 2.8 years. The Company evaluates stock awards with performance conditions as the probability that the performance conditions will be met and uses that information to estimate the date at which those performance conditions will be met in order to properly recognize stock-based compensation expense over the requisite service period. On a period basis and as of March 31, 2017, the Company reviewed the probability of achieving the performance conditions for each of the four vesting tranches of the performance-based stock options that were granted during the three months ended March 31, 2017 and in prior years and determined that it was probable that the Company would achieve the first vesting tranche in December 2017. Therefore, the Company recorded compensation expense related to performance-based stock options of $0.1 million during the three months ended March 31, 2017. The Company further determined that no compensation costs would be recognized for the second, third and fourth vesting tranches as the probability of achieving those performance conditions has not been determined.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2017
Commitments and Contingencies	10. Commitments and Contingencies Guarantees and Indemnifications Litigation Following the public announcement of Sanofi’s election to terminate the Sanofi License Agreement and the subsequent decline in our stock price, two motions were submitted to the district court at Tel Aviv, Economic Department for the certification of a class action against MannKind and certain of our officers and directors. In general, the complaints alleged that MannKind and certain of our officers and directors violated Israeli and U.S. securities laws by making materially false and misleading statements regarding the prospects for Afrezza, thereby artificially inflating the price of its common stock. The plaintiffs are seeking monetary damages. In November 2016, the district court dismissed one of the actions without prejudice. In the remaining action, the district court will be asked to determine whether Israeli or U.S. law is applicable before the case can be certified as a class action. The deadline for plaintiff’s motion regarding the applicable law is due on May 14, 2017. The Company will vigorously defend against the claims advanced. Contingencies Commitments On November 9, 2016, the supply agreement with Amphastar was amended to extend the term over which the Company is required to purchase insulin, without reducing the total amount of insulin to be purchased. Under the amendment, annual minimum quantities of insulin to be purchased for calendar years 2017 through 2023 total an aggregate purchase price of €93.0 million at March 31, 2017. The Insulin Supply Agreement specifies that Amphastar will be deemed to have satisfied its obligations with respect to quantity, if the actual quantity supplied is within plus or minus ten percent (+/- 10%) of the quantity set forth in the applicable purchase order. In addition, the aggregate cancellation fees that the Company would incur in the event that the above insulin quantities are not purchased was lowered from $5.3 million for the period October 1, 2016 through 2018 to $3.4 million over the same period. The Company has not yet purchased any insulin under the amended agreement in 2017. The annual purchase requirements under the contract are as follows: 2017 € 2.7 million 2018 € 8.9 million 2019 € 11.6 million 2020 € 15.5 million 2021 € 15.5 million 2022 € 19.4 million 2023 € 19.4 million Unless earlier terminated, the term of the Insulin Supply Agreement with Amphastar expires on December 31, 2023 and can be renewed for additional, successive two year terms upon 12 months’ written notice given prior to the end of the initial term or any additional two year term. The Company and Amphastar each have normal and customary termination rights, including termination for material breach that is not cured within a specific time frame or in the event of liquidation, bankruptcy or insolvency of the other party. In addition, the Company may terminate the Insulin Supply Agreement upon two years’ prior written notice to Amphastar without cause or upon 30 days’ prior written notice to Amphastar if a controlling regulatory authority withdraws approval for Afrezza, provided, however, in the event of a termination pursuant to either of the latter two scenarios, the provisions of the Insulin Supply Agreement require the Company to pay the full amount of all unpaid purchase commitments due over the initial term within 60 calendar days of the effective date of such termination. At March 31, 2017, the Company has other firm commitments with suppliers for an aggregate of $0.8 million.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2017
Income Taxes	11. Income Taxes Management of the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets and concluded, in accordance with the applicable accounting standards, that net deferred tax assets should be fully reserved. The Company has assessed their position with regards to uncertainty in tax positions and believes that its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position. Therefore, no reserves for uncertain income tax positions have been recorded pursuant to this guidance. Tax years since 2012 remain subject to examination by the major tax jurisdictions in which the Company is subject to tax. The Company adopted ASU 2016-09, Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting

Restructuring Charges

Restructuring Charges	3 Months Ended
	Mar. 31, 2017
Restructuring Charges	12. Restructuring Charges As of March 31, 2017 and December 31, 2016, the Company had a remaining restructuring accrual balance of $0.8 million and $1.4 million, respectively which is recorded in accrued expenses and other current liabilities in the condensed consolidated balance sheets. The Company expects to substantially pay out the remainder of this obligation by the third quarter of 2017. A reconciliation of beginning and ending liability balances for the restructuring charges is as follows (in thousands): Description 2016 2015 Total Accrual - January 1, 2017 $ 209 $ 1,167 $ 1,376 Costs paid or settled (185 ) (419 ) (604 ) Accrual - March 31, 2017 $ 24 $ 748 $ 772

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2017
Subsequent Events	13. Subsequent Events Amendment to Facility Arrangement Office Lease

Description of Business and S20

Description of Business and Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2017
Business	Business On August 11, 2014, the Company executed a license and collaboration agreement (the “Sanofi License Agreement”) with Sanofi-Aventis Deutschland GmbH, which subsequently assigned its rights and obligations under the agreement to Sanofi-Aventis U.S. LLC (“Sanofi”), pursuant to which Sanofi was responsible for global commercial, regulatory and development activities for Afrezza. On January 4, 2016, the Company received written notification from Sanofi of its election to terminate in its entirety the Sanofi License Agreement. The effective date of termination was April 4, 2016, which was when the Company assumed responsibility for worldwide development and commercialization of Afrezza. Under the terms of the transition agreement, Sanofi continued to fulfill orders for Afrezza in the United States until the Company began distributing MannKind-branded Afrezza product to major wholesalers in late July 2016. The Company began recognizing commercial product sales revenue when MannKind-branded Afrezza was dispensed from pharmacies to patients in August 2016. On November 9, 2016, the Company entered into a settlement agreement with Sanofi (the “Settlement Agreement”). Under the terms of the Settlement Agreement, the promissory note (the “Sanofi Loan Facility”) between the Company and Aventisub LLC (“Aventisub”), a Sanofi affiliate, was terminated with Aventisub agreeing to fully forgive the outstanding loan balance of $72.0 million. Sanofi also purchased $10.2 million of insulin from the Company in December 2016 under an existing insulin put option and made a cash payment of $30.6 million to the Company in early January 2017 as acceleration and in replacement of all other payments that Sanofi would otherwise have been required to make in the future pursuant to the insulin put option, without the Company being required to deliver any insulin for such payment. The Company was also relieved of its obligation to pay Sanofi $0.5 million in previously uncharged costs pursuant to the Sanofi License Agreement. The Company and Sanofi also agreed to a general release of potential claims against each other. During their initial transition of the commercial responsibilities from Sanofi, the Company utilized a contract sales organization to promote Afrezza while the Company focused its internal resources on establishing a channel strategy, entering into distribution agreements and developing co-pay assistance programs, a voucher program, data agreements and payor relationships. In early 2017, the Company recruited its own sales force and intends to continue the commercialization of Afrezza in the United States through its own commercial organization. The Company’s current strategy for future commercialization of Afrezza outside of the United States, subject to receipt of the necessary foreign regulatory approvals, is to seek and establish partnerships in foreign jurisdictions where there are appropriate commercial opportunities. As of and for the three months ended March 31, 2017, the Company has reported an accumulated deficit of $2.8 billion and has reported negative cash flow from operations for each year since inception, except for the current quarter, when the Company received the $30.6 million settlement payment from Sanofi and in 2014, when the Company received the $150.0 million upfront payment from Sanofi. At March 31, 2017, the Company’s capital resources consisted of cash and cash equivalents of $48.0 million. The Company expects to continue to incur significant expenditures to support commercial manufacturing and sales and marketing of Afrezza and the development of their product candidates. The facility agreement (the “Facility Agreement”) with Deerfield Private Design Fund II, L.P. (“Deerfield Private Design Fund”) and Deerfield Private Design International II, L.P. (collectively, “Deerfield”) that resulted in the issuance of 9.75% Senior Convertible Notes due 2019 (“2019 notes”) and the First Amendment to Facility Agreement and Registration Rights Agreement (the “First Amendment”) that resulted in the issuance of an additional tranche of 8.75% Senior Convertible Notes due 2019 (“Tranche B notes”) (see Note 6 — Borrowings) requires the Company to maintain at least $25.0 million in cash and cash equivalents or available borrowings under the loan arrangement, dated as of October 2, 2007, between the Company and The Mann Group LLC (as amended, restated, or otherwise modified as of the date hereof, “The Mann Group Loan Arrangement”), as of the last day of each fiscal quarter. Additional funding sources that are, or in certain circumstances may be, available to the Company include $30.1 million principal amount of available borrowings under The Mann Group Loan Arrangement. A portion of these available borrowings may be used to capitalize accrued interest into principal, upon mutual agreement of the parties, as it becomes due and payable under The Mann Group Loan Arrangement (see Note 5 — Related-Party Arrangements). The Company is seeking and will need to raise additional capital, whether through a sale of equity or debt securities, a strategic business collaboration with another company, the establishment of other funding facilities, licensing arrangements, asset sales or other means, in order to continue the development and commercialization of Afrezza and other product candidates and to support its other ongoing activities. The Company cannot provide assurances that such additional capital will be available on acceptable terms or at all. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. On September 14, 2016, the Company received notice from the Listing Qualifications Department of the NASDAQ Stock Market indicating that in the previous 30 consecutive business days, the bid price for the common stock closed below the minimum of $1.00 per share required for continued inclusion on the NASDAQ Global Market. The notification letter stated that the Company would be afforded 180 calendar days, or until March 13, 2017, to regain compliance with the minimum bid price requirement. On March 16, 2017, the Company received a letter from the Listing Qualifications Department of the NASDAQ Global Market indicating that the Company had regained compliance with the $1.00 minimum closing bid requirement following completion of the reverse stock split described below. On March 1, 2017, following stockholder approval, the Company’s board of directors approved a reverse stock split ratio of 1-for-5. On March 1, 2017, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment of the Company’s Amended and Restated Certificate of Incorporation to effect the 1-for-5 reverse stock split of the Company’s outstanding common stock and to reduce the authorized number of shares of the Company’s common stock from 700,000,000 to 140,000,000 shares. The Company’s common stock began trading on the NASDAQ Global Market on a split-adjusted basis when the market opened on March 3, 2017. As a result, all common stock share amounts included in these condensed consolidated financial statements have been retroactively reduced by a factor of five, and all common stock per share amounts have been increased by a factor of five, with the exception of the Company’s common stock par value. On April 18, 2017, the Company entered into an Exchange Agreement with Deerfield resulting in the cash repayment of $4.0 million under the Tranche B notes and the conversion of $1.0 million and $5.0 million of the Tranche B notes and the 2019 notes, respectively to common shares (see Note 13, Subsequent Events for disclosure of the Exchange Agreement).
Reclassifications	Reclassifications
Correction of an Immaterial Error	Correction of an Immaterial Error 2016 as Previously 2016 as (In thousands) Presented Adjustments Adjusted Common stock $ 4,784 $ (3,827 ) $ 957 Additional paid-in capital $ 2,549,212 $ 3,827 $ 2,553,039
Revenue Recognition	Revenue Recognition
Revenue Recognition- Net Revenue - Collaborations	Revenue Recognition – Net Revenue – Collaborations –
Revenue Recognition - Net Revenue - Commercial Product Sales	Revenue Recognition – Net Revenue – Commercial Product Sales – Given the Company’s limited sales history for Afrezza, the Company cannot reliably estimate expected returns of the product at the time of shipment into the distribution channel. Accordingly, the Company defers recognition of revenue on Afrezza product shipments until the right of return no longer exists, which occurs at the earlier of the time Afrezza is dispensed from pharmacies to patients or expiration of the right of return. Deferred revenue is presented net of deferred product sales discounts which are further described in Gross-to-Net Adjustments For the three months ended March 31, 2017, net revenue from commercial product sales consisted of $1.2 million of net sales of Afrezza dispensed to patients. As of March 31, 2017 and December 31, 2016, the ending balances for deferred revenue were $1.8 million and $3.4 million, on its condensed consolidated balance sheets, of which $1.8 million and $1.6 million (net of estimated gross-to-net adjustments), respectively, represents product shipped to the Company’s third-party logistics provider and wholesale distributors, but not yet dispensed to patients. The difference, as of December 31, 2016, represented deferred revenue from bulk insulin sales, which is described more fully under the heading Revenue Recognition – Revenue – Bulk Insulin Sales
Gross-to-net Adjustments	Gross-to-net Adjustments –
Wholesaler Distribution Fees	Wholesaler Distribution Fees –
Prompt Pay Discounts	Prompt Pay Discounts – Rebates and Chargebacks – The Company accounts for these rebates and chargebacks by establishing an accrual based on contractual discount rates, expected utilization under each contract and an estimate of the amount of inventory in the distribution channel that will become subject to such rebates and chargebacks based on historical payor data provided by a third-party vendor along with additional data including a forecasted participation rates. From that data, as well as input received from the commercial team, an estimated participation rate for each program is determined and applied at the rate for those sales. Any new information regarding changes in the programs’ regulations and guidelines or any changes in the Company’s government price reporting calculations that would impact the amount of the rebates will also be taken into account in determining or modifying the appropriate reserve. The time period between the date the product is sold into the channel and the date such rebates may be paid can be up to approximately six to nine months. As such, continuous monitoring of these estimates will be performed on a periodic basis, and if necessary, adjusted to reflect new facts and circumstances. Rebates and chargebacks are recognized as a reduction of gross revenue in the period the related revenue is recognized. Other Rebates and Discounts –
Patient Discount and Co-Pay Assistance Programs	Patient Discount and Co-Pay Assistance Programs –
Deferred costs	Deferred Costs from Commercial Product Sales
Revenue Recognition - Revenue - Bulk Insulin Sales	Revenue Recognition — Revenue — Bulk Insulin Sales
Cost of Goods Sold	Cost of Goods Sold
Accounts Receivable and Allowances	Accounts Receivable and Allowances
Inventories	Inventories
Recognized Loss on Purchase Commitments	Recognized Loss on Purchase Commitments
Fair Value of Financial Instruments	Fair Value of Financial Instruments
Stock-Based Compensation	Stock-Based Compensation
Warrants	Warrants
Net Income (Loss) Per Share of Common Stock	Net Loss Per Share of Common Stock The computation of basic and diluted net loss per share for the three months ended March 31, 2017 and 2016 excludes the common stock equivalents of the following potentially dilutive securities because their inclusion would be anti-dilutive: Three Months Ended March 31, 2017 2016 Restricted stock units 709,004 789,201 Senior convertible notes 814,561 814,561 Warrants 9,740,597 31,861 Stock options 5,941,408 4,820,494 17,205,570 6,456,117
Recently Issued Accounting Standards	Recently Issued Accounting Standards – In May 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606), Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date The Company will adopt the new guidance for the year beginning January 1, 2018. The Company has the option to either apply the new guidance retrospectively for all prior reporting periods presented (full retrospective) or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (modified retrospective). The Company currently anticipates it will apply the new guidance using the modified retrospective approach with the cumulative effect of initial application recognized as of January 1, 2018. The Company plans to continue analyzing the potential impacts of the application throughout 2017 and, depending on factors that may impact the results, could elect to apply the new guidance on a full retrospective basis. Currently, for commercial sales of Afrezza, the Company has limited sales and returns history, and as such is unable to reliably estimate expected returns of the product at the time of shipment into the distribution channel. Accordingly, the Company defers recognition of revenue on Afrezza product shipments until the right of return no longer exists, which occurs at the earliest of the time Afrezza is dispensed form pharmacies to patients or expiration of the right of return. The Company recognizes revenue based on Afrezza patient prescriptions dispensed, a sell-through model, as estimated by syndicated data provided by a third party. The Company also analyzes additional data points to ensure that such third-party data is reasonable, including data related to inventory movements within the channel and ongoing prescription demand. Upon adoption of the new guidance, the Company expects that it will move from its current sell-through model to a sell-to model for revenue related to commercial sales of Afrezza and will record revenue at the time title and risk of loss passes to its distributors (generally at shipment or delivery to the distributors) along with an estimate of potential returns as variable consideration. The Company also anticipates that its ability to estimate potential returns will improve with an additional 9 months of sales history that it will have obtained by January 1, 2018. Additionally, the Company has historically entered into collaborative agreements with third-parties under which periodic payments have been received. Revenue recognition for certain payments received have been deferred until the price is fixed and determinable. Further, revenue for certain payments to be received in the future has been prohibited from recognition until received. The Company expects that some of these amounts will be considered variable consideration and may be able to be recognized earlier under the new guidance. The Company has begun its evaluation of the impact of adoption and plans to continue its evaluation throughout 2017. The financial impact upon the adoption will be dependent upon a number of factors including; the amount of revenue that has been deferred under the sell-through model for Afrezza, the amount of the revenue deferred under collaborative arrangements and the Company’s estimate of variable consideration at the date of adoption. At this time, the Company has not completed its evaluation of the inputs, assumptions and methodologies that will be used recognize revenue related to variable consideration under the new guidance. In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments Overall (Subtopic 825-10) Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 84 In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash.

Description of Business and S21

Description of Business and Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2017
Summary of Correction of Error for Prior Period Presented	The Company has revised the historical consolidated financial information presented herein to reflect the correction of this error for the prior period presented. 2016 as Previously 2016 as (In thousands) Presented Adjustments Adjusted Common stock $ 4,784 $ (3,827 ) $ 957 Additional paid-in capital $ 2,549,212 $ 3,827 $ 2,553,039
Schedule of Potentially Dilutive Common Stock Equivalent Securities	The computation of basic and diluted net loss per share for the three months ended March 31, 2017 and 2016 excludes the common stock equivalents of the following potentially dilutive securities because their inclusion would be anti-dilutive: Three Months Ended March 31, 2017 2016 Restricted stock units 709,004 789,201 Senior convertible notes 814,561 814,561 Warrants 9,740,597 31,861 Stock options 5,941,408 4,820,494 17,205,570 6,456,117

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2017
Components of Inventories	Inventories consist of the following (in thousands): March 31, 2017 December 31, 2016 Work-in-process $ 3,296 $ 2,120 Finished goods 402 211 Total inventory $ 3,698 $ 2,331

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2017
Property and Equipment, Net	Property and equipment consist of the following (in thousands): Estimated Useful Life (Years) March 31, 2017 December 31, 2016 Land — $ 875 $ 875 Buildings 39-40 17,389 17,389 Building improvements 5-40 34,957 34,957 Machinery and equipment 3-15 62,992 62,992 Furniture, fixtures and office equipment 5-10 3,556 3,556 Computer equipment and software 3 8,531 8,531 Construction in progress — 202 202 128,502 128,502 Less accumulated depreciation (100,020 ) (99,575 ) Total property and equipment, net $ 28,482 $ 28,927

Accrued Expenses and Other Cu24

Accrued Expenses and Other Current Liabilities (Tables)	3 Months Ended
	Mar. 31, 2017
Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consist of the following (in thousands): March 31, 2017 December 31, 2016 Salary and related expenses $ 3,900 $ 3,814 Current portion of milestone rights liability 1,643 — Professional fees 1,505 875 Discounts and allowances for commercial product sales 996 754 Sales and marketing services 821 144 Restructuring 772 1,376 Accrued interest 221 619 Other 799 355 Accrued expenses and other current liabilities $ 10,657 $ 7,937

Borrowings (Tables)

Borrowings (Tables)	3 Months Ended
	Mar. 31, 2017
Summary of Borrowings	Borrowings consist of the following (in thousands): March 31, 2017 December 31, 2016 Facility Financing Obligation (2019 Notes) Principal amount $ 75,000 $ 75,000 Unamortized debt discount (3,205 ) (3,661 ) Net carrying amount $ 71,795 $ 71,339 Senior Convertible Notes (2018 Notes) Principal amount $ 27,690 $ 27,690 Unamortized premium 367 426 Unaccreted debt issuance costs (415 ) (481 ) Net carrying amount $ 27,642 $ 27,635 Note payable to principal stockholder - net carrying amount $ 49,521 $ 49,521
Accretion of Debt Issuance Cost and Debt Discount	Accretion of debt issuance cost and debt discount in connection with the Facility Agreement during the three months ended March 31, 2017 and 2016 are as follows (in thousands): Three Months Ended March 31, 2017 2016 Accretion expense - debt issuance cost $ 9 $ 9 Accretion expense - debt discount $ 447 $ 419

Fair Value of Financial Instr26

Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2017
Fair Value of Financial Instruments	The following tables set forth the fair value of the Company’s financial instruments (in millions): As of March 31, 2017 Carrying Value Level 1 Level 2 Level 3 Total Financial liabilities: Senior convertible notes $ 27.6 $ — $ — $ 23.1 $ 23.1 Facility financing obligation 71.8 — — 74.8 74.8 Milestone rights 8.9 — — 18.9 18.9 Warrant liability (at recurring fair value) 0.8 — — 0.8 0.8 Total financial liabilities $ 109.1 $ — $ — $ 117.6 $ 117.6 As of December 31, 2016 Carrying Value Level 2 Level 2 Level 3 Total Financial liabilities: Senior convertible notes $ 27.6 $ — $ — $ 22.9 $ 22.9 Facility financing obligation 71.3 — — 74.5 74.5 Milestone rights 8.9 — — 18.4 18.4 Warrant liability (at recurring fair value) 7.4 — — 7.4 7.4 Total financial liabilities $ 115.2 $ — $ — $ 123.2 $ 123.2
Fair Values of Warrant Liability which Include Level 3 Instruments	The following table provides a roll forward of the fair value of the warrant liability which is the only Level 3 financial instrument that is carried at fair value (in millions): Warrants Fair value, January 1, 2017 $ 7.4 Additions — Changes in fair value (6.6 ) Payments — Fair value, March 31, 2017 $ 0.8

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2017
Annual Purchase Requirements under Contract	The annual purchase requirements under the contract are as follows: 2017 € 2.7 million 2018 € 8.9 million 2019 € 11.6 million 2020 € 15.5 million 2021 € 15.5 million 2022 € 19.4 million 2023 € 19.4 million

Restructuring Charges (Tables)

Restructuring Charges (Tables)	3 Months Ended
	Mar. 31, 2017
Reconciliation of Beginning and Ending Liability Balances for Restructuring Charges	A reconciliation of beginning and ending liability balances for the restructuring charges is as follows (in thousands): Description 2016 2015 Total Accrual - January 1, 2017 $ 209 $ 1,167 $ 1,376 Costs paid or settled (185 ) (419 ) (604 ) Accrual - March 31, 2017 $ 24 $ 748 $ 772

Description of Business and S29

Description of Business and Significant Accounting Policies - Additional Information (Detail)	Apr. 18, 2017USD ($)	Mar. 01, 2017shares	Nov. 09, 2016USD ($)	Jan. 31, 2017USD ($)	Mar. 31, 2017USD ($)Distributor$ / sharesshares	Mar. 31, 2016USD ($)	Dec. 31, 2016USD ($)Distributorshares	Sep. 30, 2016shares	Dec. 31, 2015USD ($)	Sep. 23, 2014
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Net revenue from collaboration					$ 63,000
Accumulated deficit					(2,753,889,000)		$ (2,737,565,000)
Cash and cash equivalents					$ 47,978,000	$ 27,653,000	$ 22,895,000		$ 59,074,000
Stock market bidding requirements, description					On September 14, 2016, the Company received notice from the Listing Qualifications Department of the NASDAQ Stock Market indicating that in the previous 30 consecutive business days, the bid price for the common stock closed below the minimum of $1.00 per share required for continued inclusion on the NASDAQ Global Market.
Minimum closing bid requirement, price per share | $ / shares					$ 1
Stock split of common stock		0.2
Common stock, shares authorized | shares		140,000,000			140,000,000		140,000,000	700,000,000
Reverse stock split, description					The Company’s board of directors approved a reverse stock split ratio of 1-for-5. On March 1, 2017, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment of the Company’s Amended and Restated Certificate of Incorporation to effect the 1-for-5 reverse stock split of the Company’s outstanding common stock and to reduce the authorized number of shares of the Company’s common stock from 700,000,000 to 140,000,000 shares. The Company’s common stock began trading on the NASDAQ Global Market on a split-adjusted basis when the market opened on March 3, 2017. As a result, all common stock share amounts included in these condensed consolidated financial statements have been retroactively reduced by a factor of five, and all common stock per share amounts have been increased by a factor of five, with the exception of the Company’s common stock par value.
Deferred revenue					$ 1,844,000		$ 3,419,000
Net revenue - commercial product sales					$ 1,196,000
Number of wholesale distributors | Distributor					3
Percentage of product shipments to wholesale distributors					93.00%
Product sales					$ 3,009,000
Cash discount as incentive for prompt payment					2.00%
Deferred revenue from sale of raw insulin					$ 0		$ 1,800,000
Number of wholesale distributors accounted for gross accounts receivable | Distributor					3		3
Allowance for doubtful accounts					$ 0		$ 0
Percentage of accounts receivable from major wholesale distributors					92.00%		95.00%
Loss on purchase commitments, number of contracts recognized					0		0
License and Collaboration Agreement with Sanofi
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Gain on extinguishment of debt			$ 500,000
Senior notes, effective interest rate										8.50%
Third party logistics
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Deferred revenue					$ 1,800,000		$ 1,600,000
Insulin Put
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Net revenue from collaboration							10,200,000
AFREZZA product sales
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Product sales revenue gross to net adjustments					$ 400,000	0
Product sales revenue gross to net adjustments percentage					27.00%
Product sales						$ 0
Less portion of commitment asset
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Cash repayment of senior notes under exchange agreement					$ 4,000,000
Conversion of notes to common shares, value					$ 1,000,000
Minimum | AFREZZA product sales
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Sales return right following product expiration in months					6 months
Maximum | AFREZZA product sales
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Sales return right following product expiration in months					12 months
Senior convertible notes due December 31, 2019
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Conversion of notes to common shares, value					$ 5,000,000
Allowance for Sales Returns
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Allowance for returns					300,000		0
Principal stockholder | Loan Arrangement
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Amount available for future borrowings					30,100,000		30,100,000
Principal stockholder | Senior convertible notes due December 31, 2019 | Loan Arrangement
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Amount available for future borrowings					30,100,000
Sanofi-Aventis Deutschland GmbH | License and Collaboration Agreement with Sanofi
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Net revenue from collaboration					172,000,000
Up-front fee					150,000,000
Sanofi-Aventis Deutschland GmbH | Insulin Put | License and Collaboration Agreement with Sanofi
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Net revenue from collaboration					19,400,000
Sanofi-Aventis Deutschland GmbH | AFREZZA product sales | License and Collaboration Agreement with Sanofi
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Net revenue from collaboration					$ 17,500,000
Sanofi-Aventis Deutschland GmbH | Put Option
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Payment for insulin put option				$ 30,600,000			$ 30,600,000
Aventisub LLC
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Outstanding loan balance forgive			$ 72,000,000
Deerfield | Senior convertible notes due December 31, 2019
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Senior notes, effective interest rate					9.75%
Deerfield | Senior convertible notes due December 31, 2019 | Less portion of commitment asset
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Senior notes, effective interest rate					8.75%
Deerfield | Senior convertible notes due December 31, 2019 | Less portion of commitment asset | Subsequent Event
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Cash repayment of senior notes under exchange agreement	$ 4,000,000
Conversion of notes to common shares, value	1,000,000
Deerfield | Senior convertible notes due December 31, 2019 | Tranche 1 Notes | Subsequent Event
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Conversion of notes to common shares, value	$ 5,000,000
Deerfield | Senior convertible notes due December 31, 2019 | Minimum | Less portion of commitment asset
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Available amount of credit facility under covenant restrictions					$ 25,000,000

Description of Business and S30

Description of Business and Significant Accounting Policies - Summary of Correction of Error for Prior Period Presented (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Common stock	$ 958	$ 957
Additional paid-in capital	$ 2,554,230	2,553,039
Previously Presented
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Common stock		4,784
Additional paid-in capital		2,549,212
Adjustments
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Common stock		(3,827)
Additional paid-in capital		$ 3,827

Schedule of Potentially Dilutiv

Schedule of Potentially Dilutive Common Stock Equivalent Securities (Detail) - shares	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share	17,205,570	6,456,117
Restricted Stock Units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share	709,004	789,201
Senior Convertible Notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share	814,561	814,561
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share	9,740,597	31,861
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share	5,941,408	4,820,494

Components of Inventories (Deta

Components of Inventories (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Inventory [Line Items]
Work-in-process	$ 3,296	$ 2,120
Finished goods	402	211
Total inventory	$ 3,698	$ 2,331

Property and Equipment, Net (De

Property and Equipment, Net (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Property and equipment - gross	$ 128,502	$ 128,502
Less accumulated depreciation	(100,020)	(99,575)
Total property and equipment, net	28,482	28,927
Land
Property, Plant and Equipment [Line Items]
Property and equipment - gross	875	875
Buildings
Property, Plant and Equipment [Line Items]
Property and equipment - gross	$ 17,389	17,389
Buildings | Minimum
Property, Plant and Equipment [Line Items]
Estimated Useful Life (Years)	39 years
Buildings | Maximum
Property, Plant and Equipment [Line Items]
Estimated Useful Life (Years)	40 years
Building Improvements
Property, Plant and Equipment [Line Items]
Property and equipment - gross	$ 34,957	34,957
Building Improvements | Minimum
Property, Plant and Equipment [Line Items]
Estimated Useful Life (Years)	5 years
Building Improvements | Maximum
Property, Plant and Equipment [Line Items]
Estimated Useful Life (Years)	40 years
Machinery and Equipment
Property, Plant and Equipment [Line Items]
Property and equipment - gross	$ 62,992	62,992
Machinery and Equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated Useful Life (Years)	3 years
Machinery and Equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated Useful Life (Years)	15 years
Furniture, fixtures and office equipment
Property, Plant and Equipment [Line Items]
Property and equipment - gross	$ 3,556	3,556
Furniture, fixtures and office equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated Useful Life (Years)	5 years
Furniture, fixtures and office equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated Useful Life (Years)	10 years
Computer Equipment and Software
Property, Plant and Equipment [Line Items]
Estimated Useful Life (Years)	3 years
Property and equipment - gross	$ 8,531	8,531
Construction in Progress
Property, Plant and Equipment [Line Items]
Property and equipment - gross	$ 202	$ 202

Property and Equipment - Additi

Property and Equipment - Additional Information (Detail) - USD ($) $ in Thousands	Feb. 17, 2017	Jan. 06, 2017	Mar. 31, 2017	Mar. 31, 2016
Depreciation and Other Amortization Expenses [Line Items]
Depreciation and amortization expense			$ 400	$ 600
Cash received from property, plant and equipment			$ 16,651	$ 17
Land, Buildings and Improvements | California
Depreciation and Other Amortization Expenses [Line Items]
Amount of divestiture of long-lived		$ 17,300
Cash received from property, plant and equipment	$ 17,300
Net cash received from property, plant and equipment		16,700
Payments for commissions and other fees		$ 600

Accrued Expenses and Other Cu35

Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Accrued Expenses and Other Current Liabilities [Line Items]
Salary and related expenses	$ 3,900	$ 3,814
Current portion of milestone rights liability	1,643
Professional fees	1,505	875
Discounts and allowances for commercial product sales	996	754
Sales and marketing services	821	144
Restructuring	772	1,376
Accrued interest	221	619
Other	799	355
Accrued expenses and other current liabilities	$ 10,657	$ 7,937

Related-Party Arrangements - Ad

Related-Party Arrangements - Additional Information (Detail)	1 Months Ended			3 Months Ended
	May 31, 2015USD ($)ft²	Oct. 31, 2013USD ($)	Oct. 31, 2007USD ($)	Mar. 31, 2017USD ($)	Mar. 31, 2016USD ($)	Dec. 31, 2016USD ($)
Related Party Transaction [Line Items]
Accrued interest of related party debt				$ 10,000,000		$ 9,300,000
Interest expense on note payable principal stockholder				$ 714,000	$ 721,000
Principal stockholder
Related Party Transaction [Line Items]
Loan agreement with related party		$ 370,000,000	$ 350,000,000
Principal stockholder | Amended Agreement
Related Party Transaction [Line Items]
Maturity date				Jan. 5, 2020
Principal stockholder | Loan Arrangement
Related Party Transaction [Line Items]
Principal amount outstanding under credit facility				$ 49,500,000
Amount available for future borrowings				$ 30,100,000		$ 30,100,000
Fixed borrowing rate				5.84%
Related party transaction prepayment period				90 days
Aggregate principal amount cancelled				$ 105,000,000
Principal stockholder | Loan Arrangement | Maximum
Related Party Transaction [Line Items]
Amount prepaid for cancellation of indebtedness				$ 200,000,000
Principal stockholder | Loan Arrangement | Minimum
Related Party Transaction [Line Items]
Number of months advances outstanding				12 months
Related Party Debt | Letter Agreement
Related Party Transaction [Line Items]
Description of variable rate interest				The interest rate will increase to the one-year LIBOR calculated on the date of the initial advance or in effect on the date of default, whichever is greater, plus 5% per annum.
Related Party Debt | Letter Agreement | LIBOR
Related Party Transaction [Line Items]
Interest rate (LIBOR)				5.00%
Mann Foundation | Sublease Agreement
Related Party Transaction [Line Items]
Area of office space leased | ft²	12,500
Lease expiration period				2017-04
Lease payment				$ 62,000	$ 65,000
Amount of leases renewed per month	$ 21,000

Summary of Borrowings (Detail)

Summary of Borrowings (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Note payable to principal stockholder - net carrying amount	$ 49,521	$ 49,521
Senior convertible notes due December 31, 2019
Debt Instrument [Line Items]
Principal amount	75,000	75,000
Unamortized debt discount	(3,205)	(3,661)
Net carrying amount	71,795	71,339
5.75% Senior convertible notes due August 15, 2018
Debt Instrument [Line Items]
Principal amount	27,690	27,690
Unamortized premium	367	426
Unaccreted debt issuance costs	(415)	(481)
Net carrying amount	$ 27,642	$ 27,635

Borrowings - Additional Informa

Borrowings - Additional Information (Detail)	Aug. 10, 2015d$ / shares	Mar. 31, 2017USD ($)	Mar. 31, 2016USD ($)	Dec. 31, 2014USD ($)shares	Dec. 31, 2016USD ($)	Jul. 28, 2015USD ($)	Jul. 01, 2013USD ($)
Debt Instrument [Line Items]
Facility Agreement, total principle payment in 2017		$ 20,000,000
Facility Agreement, total principle payment in 2018		20,000,000
Facility Agreement, total principle payment in 2019		35,000,000
Other liabilities		117,600,000			$ 123,200,000
Milestone Rights Liability
Debt Instrument [Line Items]
Other liabilities		18,900,000			18,400,000
Less portion of commitment asset
Debt Instrument [Line Items]
Cash repayment of senior notes under exchange agreement		4,000,000
Conversion of debt		$ 1,000,000
Deerfield
Debt Instrument [Line Items]
Principal repayment schedule, start date		Jul. 1, 2016
Principal repayment schedule, end date		Dec. 9, 2019
Conversion Option, value				$ 93,500,000
Conversion Option, shares | shares				3,464,616
Amortization of notes premium		$ 447,000	$ 419,000
Deerfield | Milestone Rights Liability
Debt Instrument [Line Items]
Long term liability		8,900,000
Deerfield | Milestone Rights Liability | Maximum
Debt Instrument [Line Items]
Contingent liability for milestone payments		90,000,000					$ 90,000,000
Deerfield | Tranche 1 Notes
Debt Instrument [Line Items]
Conversion Option, value				$ 20,000,000
Deerfield | Tranche 2 note
Debt Instrument [Line Items]
Conversion Option, value				33,500,000
Deerfield | Tranche 3 note
Debt Instrument [Line Items]
Conversion Option, value				$ 40,000,000
Senior convertible notes due December 31, 2019
Debt Instrument [Line Items]
Debt facility principal amount		75,000,000			75,000,000
Conversion of debt		5,000,000
Carrying value		71,795,000			71,339,000
Senior convertible notes due December 31, 2019 | Deerfield
Debt Instrument [Line Items]
Debt facility principal amount		$ 55,000,000
Senior notes, effective interest rate		9.75%
Accrued expenses		$ 1,600,000
Other current liabilities		1,600,000
Other liabilities		8,900,000
Senior convertible notes due December 31, 2019 | Deerfield | Milestone Rights Liability
Debt Instrument [Line Items]
Long term liability		7,300,000			8,900,000
Senior convertible notes due December 31, 2019 | Deerfield | Milestone Rights Liability | Danbury Facility
Debt Instrument [Line Items]
Carrying value		28,500,000
Senior convertible notes due December 31, 2019 | Deerfield | Less portion of commitment asset
Debt Instrument [Line Items]
Debt facility principal amount		$ 20,000,000
Senior notes, effective interest rate		8.75%
Senior convertible notes due December 31, 2019 | Deerfield | Less portion of commitment asset | Minimum
Debt Instrument [Line Items]
Available amount of credit facility under covenant restrictions		$ 25,000,000
Senior convertible notes due December 31, 2019 | Deerfield | Less portion of commitment asset | Minimum | Facility Agreement
Debt Instrument [Line Items]
Available amount of credit facility under covenant restrictions		25,000,000
5.75% Senior convertible notes due August 15, 2018
Debt Instrument [Line Items]
Debt facility principal amount		27,690,000			27,690,000
Senior notes, effective interest rate	5.75%
Carrying value		$ 27,642,000			$ 27,635,000
No of convertible shares	29
Principal amount per share | $ / shares	$ 1,000
Conversion price of shares | $ / shares	$ 34
Percentage of repurchase price	100.00%
Debt Instrument, redemption description		On or after the date that is one year following the original issue date of the 2018 notes, the Company will have the right to redeem for cash all or part of the 2018 notes if the last reported sale price of its common stock exceeds 130% of the conversion price then in effect for 20 or more trading days during the 30 consecutive trading day period ending on the trading day immediately prior to the date of the redemption notice. The redemption price will equal the sum of 100% of the principal amount of the 2018 notes to be redeemed, plus accrued and unpaid interest.
Percentage of conversion price equaling stock price	130.00%
Number of trading days | d	20
Consecutive trading days	30 days
Debt Issuance Cost						$ 800,000
Amortization of notes premium		$ 59,000	57,000
Accretion of debt issuance costs		$ 66,000	$ 62,000

Accretion of Debt Issuance Cost

Accretion of Debt Issuance Cost and Debt Discount in Connection with Facility Financing Agreement (Detail) - Deerfield - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Debt Instrument [Line Items]
Accretion expense - debt issuance cost	$ 9	$ 9
Accretion expense - debt discount	$ 447	$ 419

Collaboration Arrangements - Ad

Collaboration Arrangements - Additional Information (Detail) - USD ($)	Dec. 30, 2016	Nov. 09, 2016	Feb. 10, 2016	Jan. 04, 2016	Jan. 31, 2017	Sep. 30, 2016	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016	Dec. 31, 2015	Sep. 23, 2014
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net revenue from collaboration							$ 63,000
Paid-in-kind interest								$ 1,168,000
Insulin Put
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net revenue from collaboration									$ 10,200,000
Sanofi-Aventis Deutschland GmbH | Put Option
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Payment for insulin put option					$ 30,600,000				$ 30,600,000
Aventisub LLC
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Outstanding loan balance forgiven		$ 72,000,000
License and Collaboration Agreement with Sanofi
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Profits and losses sharing percentage							35.00%
Termination date				Apr. 4, 2016
Maximum secured loan facility											$ 175,000,000
Senior notes, effective interest rate											8.50%
Gain on extinguishment of debt		$ 500,000
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred revenue - nonrefundable license fee							$ 150,000,000
Net revenue from collaboration							$ 172,000,000
Profits and losses sharing percentage							65.00%
Milestone receivable							$ 25,000,000
Deferred cost										$ 13,500,000
Secured loan facility, amount borrowed			$ 17,900,000							44,500,000
Secured loan facility, amount owed						$ 71,200,000
Paid-in-kind interest						$ 5,800,000
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | Up Front Payment [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net revenue from collaboration							150,000,000
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | Milestone Payment One
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net revenue from collaboration							25,000,000
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | Milestone Payment Two
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net revenue from collaboration							25,000,000
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | AFREZZA product sales
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred revenue - nonrefundable license fee										17,500,000
Net revenue from collaboration							17,500,000
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | Insulin Put
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net revenue from collaboration							19,400,000
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | Operating loss Sharing
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net revenue from collaboration							(64,900,000)
Company's total portion of loss sharing										$ 57,700,000
Receptor
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Nonrefundable payments							400,000
Nonrefundable option exercise and license fee	$ 1,000,000
Reduction in research and development expense							400,000
Deferred revenue - nonrefundable license fee							$ 1,000,000
Deferred revenue recognition period							4 years
Net revenue from collaboration							$ 100,000

Fair Value of Financial Instr41

Fair Value of Financial Instruments - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016	Jul. 01, 2013
Fair Value of Financial Instruments [Line Items]
Cash equivalents, money market funds	$ 47,400,000	$ 20,500,000
Fair value of the liability, percentage increase	8.00%
Fair value of the liability, percentage decrease	7.00%
Maximum
Fair Value of Financial Instruments [Line Items]
Probabilities of meeting the milestones, percentage decrease	10.00%
Fair value of the liability, percentage decrease	30.00%
Minimum
Fair Value of Financial Instruments [Line Items]
Probabilities of meeting the milestones, percentage decrease	5.00%
Fair value of the liability, percentage decrease	17.00%
Milestone Rights Liability | Deerfield
Fair Value of Financial Instruments [Line Items]
Long term liability	$ 8,900,000
Milestone Rights Liability | Deerfield | Maximum
Fair Value of Financial Instruments [Line Items]
Contingent liability for milestone payments	90,000,000		$ 90,000,000
Milestone Rights Liability | Senior convertible notes due December 31, 2019 | Deerfield
Fair Value of Financial Instruments [Line Items]
Long term liability	7,300,000	8,900,000
Warrant Liability
Fair Value of Financial Instruments [Line Items]
Fair value of warrants liability	$ 800,000	$ 7,400,000
Valuation technique	Monte Carlo valuation pricing model
Fair value assumption, risk-free rate	1.24%
Warrant liability fair value assumptions, dividend yield	0.00%
Warrant liability fair value assumptions, remaining term	1 year 1 month 6 days
Fair value assumption, stock price volatility	100.00%
Fair Value, Inputs, Level 3 | Milestone Rights Liability
Fair Value of Financial Instruments [Line Items]
Fair value of warrants liability	$ 18,900,000
Fair Value, Inputs, Level 3 | Market Approach Valuation Technique | 5.75% Senior convertible notes due August 15, 2018 | Senior Convertible Notes
Fair Value of Financial Instruments [Line Items]
Fair value assumption, risk-free rate	20.00%
Fair value assumption, stock price volatility	115.00%
Fair Value, Inputs, Level 3 | Income Approach Valuation Technique | Senior convertible notes due December 31, 2019
Fair Value of Financial Instruments [Line Items]
Market discount rate	12.00%
Fair Value, Inputs, Level 3 | Income Approach Valuation Technique | Milestone Rights Liability
Fair Value of Financial Instruments [Line Items]
Market discount rate	14.50%

Fair Value of Financial Instr42

Fair Value of Financial Instruments (Detail) - USD ($) $ in Millions	Mar. 31, 2017	Dec. 31, 2016
Financial liabilities:
Financial liabilities fair value	$ 117.6	$ 123.2
Warrant Liability
Financial liabilities:
Financial liabilities fair value	0.8	7.4
Milestone Rights Liability
Financial liabilities:
Financial liabilities fair value	18.9	18.4
Senior Convertible Notes | Senior Convertible Notes
Financial liabilities:
Financial liabilities fair value	23.1	22.9
Facility Financing Obligation
Financial liabilities:
Financial liabilities fair value	74.8	74.5
Carrying Value
Financial liabilities:
Financial liabilities fair value	109.1	115.2
Carrying Value | Warrant Liability
Financial liabilities:
Financial liabilities fair value	0.8	7.4
Carrying Value | Milestone Rights Liability
Financial liabilities:
Financial liabilities fair value	8.9	8.9
Carrying Value | Senior Convertible Notes | Senior Convertible Notes
Financial liabilities:
Financial liabilities fair value	27.6	27.6
Carrying Value | Facility Financing Obligation
Financial liabilities:
Financial liabilities fair value	71.8	71.3
Estimate of Fair Value Measurement | Fair Value, Inputs, Level 3
Financial liabilities:
Financial liabilities fair value	117.6	123.2
Estimate of Fair Value Measurement | Fair Value, Inputs, Level 3 | Warrant Liability
Financial liabilities:
Financial liabilities fair value	0.8	7.4
Estimate of Fair Value Measurement | Fair Value, Inputs, Level 3 | Milestone Rights Liability
Financial liabilities:
Financial liabilities fair value	18.9	18.4
Estimate of Fair Value Measurement | Senior Convertible Notes | Fair Value, Inputs, Level 3 | Senior Convertible Notes
Financial liabilities:
Financial liabilities fair value	23.1	22.9
Estimate of Fair Value Measurement | Facility Financing Obligation | Fair Value, Inputs, Level 3
Financial liabilities:
Financial liabilities fair value	$ 74.8	$ 74.5

Fair Value of Warrant Liability

Fair Value of Warrant Liability Carried at Fair Value (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2017USD ($)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair values of financial liabilities, beginning balance	$ 123.2
Fair values of financial liabilities, ending balance	117.6
Warrant Liability
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair values of financial liabilities, beginning balance	7.4
Additions	0
Changes in fair value	(6.6)
Payments	0
Fair values of financial liabilities, ending balance	$ 0.8

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail)	3 Months Ended		12 Months Ended
	Mar. 31, 2017USD ($)Tranche$ / sharesshares	Mar. 31, 2016USD ($)	Dec. 31, 2016USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Excess tax benefits related to windfalls			$ 11,600,000
Stock-based compensation expense	$ 1,300,000	$ 1,300,000
Number of restricted stock units issued | shares	77,680
Weighted average grant date fair value of the stock options granted | $ / shares	$ 1.86
Number of equal tranches | Tranche	4
Weighted average vesting period for unrecognized compensation expense	2 years 9 months 18 days
Vest in Four Equal Tranches
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate number of shares granted to awards, share-based compensation arrangements | shares	463,000
Vest Over Four Year Period
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate number of shares granted to awards, share-based compensation arrangements | shares	120,180
Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense related to options	$ 100,000
Tranche achievement date	2017-12
Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost, share-based compensation arrangements	$ 0
Tranche Three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost, share-based compensation arrangements	0
Tranche Four
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost, share-based compensation arrangements	$ 0
Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair value of the stock options granted | $ / shares	$ 2.70
Aggregate number of shares granted to awards, share-based compensation arrangements | shares	583,180
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
Unrecognized compensation expense related to options	$ 3,300,000
Stock Options | Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of stock granted, share-based compensation arrangements	1,100,000
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of Restricted stock options granted , value	$ 200,000
Weighted average grant date fair value of the stock options granted | $ / shares	$ 2.70
Unrecognized compensation expense related to non-option	$ 4,100,000
Options vest over vesting period
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense related to options	$ 3,800,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) € in Millions	3 Months Ended	24 Months Ended
	Mar. 31, 2017EUR (€)	Oct. 01, 2018USD ($)	Mar. 31, 2017USD ($)	Jul. 01, 2013USD ($)
Commitments and Contingencies [Line Items]
Purchase commitment amount under Insulin Supply Agreement | €	€ 93
Supply Agreement expiration period	Dec. 31, 2023
Supply Agreement renewal period	2 years
Scenario Forecast
Commitments and Contingencies [Line Items]
Purchase commitment cancellation fees		$ 3,400,000
Scenario Forecast | Before Amendment
Commitments and Contingencies [Line Items]
Purchase commitment cancellation fees		$ 5,300,000
Supply Commitment
Commitments and Contingencies [Line Items]
Purchase commitment obligation			$ 800,000
Deerfield | Milestone Rights Liability | Maximum
Commitments and Contingencies [Line Items]
Contingent liability for milestone payments			$ 90,000,000	$ 90,000,000

Annual Purchase Requirements un

Annual Purchase Requirements under Contract (Detail) € in Millions	Mar. 31, 2017EUR (€)
Annual Purchase Requirements under Contract
2,017	€ 2.7
2,018	8.9
2,019	11.6
2,020	15.5
2,021	15.5
2,022	19.4
2,023	€ 19.4

Restructuring Charges - Additio

Restructuring Charges - Additional information (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Restructuring Cost and Reserve [Line Items]
Restructuring	$ 772	$ 1,376
Accrued Expenses and Other Current Liabilities
Restructuring Cost and Reserve [Line Items]
Restructuring	$ 800	$ 1,400

Reconciliation of Beginning and

Reconciliation of Beginning and Ending Liability Balances for Restructuring Charges (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2017USD ($)
Restructuring Cost and Reserve [Line Items]
Accrual - Beginning balance	$ 1,376
Costs paid or settled	(604)
Accrual - Ending balance	772
Twenty Sixteen Restructuring Plan
Restructuring Cost and Reserve [Line Items]
Accrual - Beginning balance	209
Costs paid or settled	(185)
Accrual - Ending balance	24
Twenty Fifteen Restructuring Plan
Restructuring Cost and Reserve [Line Items]
Accrual - Beginning balance	1,167
Costs paid or settled	(419)
Accrual - Ending balance	$ 748

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - USD ($)	May 05, 2017	Apr. 18, 2017	Mar. 31, 2017	Dec. 31, 2014
Senior convertible notes due December 31, 2019
Subsequent Event [Line Items]
Conversion of notes to common shares, value			$ 5,000,000
Less portion of commitment asset
Subsequent Event [Line Items]
Cash repayment of senior notes under exchange agreement			4,000,000
Conversion of notes to common shares, value			$ 1,000,000
Deerfield
Subsequent Event [Line Items]
Conversion of notes to common shares, shares				3,464,616
Deerfield | Less portion of commitment asset | Senior convertible notes due December 31, 2019 | Subsequent Event
Subsequent Event [Line Items]
Cash repayment of senior notes under exchange agreement		$ 4,000,000
Conversion of notes to common shares, value		$ 1,000,000
Deerfield | Tranche B Exchange Shares | Senior convertible notes due December 31, 2019 | Subsequent Event
Subsequent Event [Line Items]
Conversion of notes to common shares, shares		869,565
Exchange price per share		$ 1.15
Deerfield | Tranche 1 Notes | Senior convertible notes due December 31, 2019 | Subsequent Event
Subsequent Event [Line Items]
Conversion of notes to common shares, value		$ 5,000,000
Conversion of notes to common shares, shares		4,347,826
Russell Ranch Road II LLC [Member] | Subsequent Event
Subsequent Event [Line Items]
Lease monthly rental payments	$ 40,951
Percentage of annual increase in lease payment	3.00%
Lease expiration period	65 months
Lease renewal option	5 years